LC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-06. Numbers and descriptions here follow the published literature rather than marketing material.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description varies by grade |
| Solubility class | Freely soluble in water | Polar nucleotide; less soluble in organic solvents |
| Typical storage temperature | -20°C or below | Protect from moisture and light; desiccated |
| Common analytical method | HPLC-UV or LC-MS | Used for identity and purity; NMR for structure |
| Hygroscopicity | Hygroscopic | Absorbs moisture; keep sealed |
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
This must be especially the case for LCRs found in highly expressed proteins, since they should also have a great impact on the energy burden of protein translation. Thus, any prokaryotic LCRs that constitute evolutionary accidents with no functional significance should not be fixed by genetic drift and consequently should not demonstrate any levels of conservation among moderately distant evolutionary relatives. On the contrary, any LCR found among homologs of several moderately distant prokaryotic species should very probably reserve a functional role.
==== The cancelled meeting ==== In early December Thatcher had two ad hoc meetings with Heseltine, Brittan, Tebbit, William Whitelaw (Deputy Prime Minister), Geoffrey Howe (Foreign Secretary) and Nigel Lawson (Chancellor of the Exchequer). Howe and Tebbit were not unsympathetic to Heseltine's proposed consortium, and the decision was deferred to the Cabinet Economic Affairs Committee (E(A)) on Monday 9 December 1985. After that meeting Thatcher, who complained that three hours had been spent discussing a company with a market capitalisation of only £30m (a tiny amount in government terms), allowed Heseltine until 4pm on Friday 13 December to submit a viable proposal for a European deal. He did (with British Aerospace and GEC now part of his consortium), but Westland's directors rejected it. Heseltine had expected that there would be a second meeting of E(A) to discuss his consortium, but no such meeting was called; Thatcher later stated that the Monday meeting had agreed to leave the decision to Westland to take, but it later emerged that Ridley and Lord Young had placed such a meeting in their diaries and had been told by Number Ten that it had been cancelled. Heseltine threatened resignation for the first time. Heseltine raised his concerns with Tebbit, Whitelaw and John Wakeham (Chief Whip). At Cabinet on Thursday 12 December he had an angry exchange with Thatcher about the cancelled meeting, but Westland was not on the agenda for the meeting and Thatcher refused to permit a discussion on the matter, arguing that Cabinet could not do so without the necessary papers.
== Histidine-specific protein kinases == Histidine kinases (EC 2.7.13.-) are structurally distinct from most other protein kinases and are found mostly in prokaryotes as part of two-component signal transduction mechanisms. A phosphate group from ATP is first added to a histidine residue within the kinase, and later transferred to an aspartate residue on a 'receiver domain' on a different protein, or sometimes on the kinase itself. The aspartyl phosphate residue is then active in signaling. Histidine kinases are found widely in prokaryotes, as well as in plants, fungi and eukaryotes. The pyruvate dehydrogenase family of kinases in animals is structurally related to histidine kinases, but instead phosphorylate serine residues, and probably do not use a phospho-histidine intermediate.
Sources: en.wikipedia.org
Pork heart can be stewed, poached, braised, or made into sausage. The Balinese oret is a sort of blood sausage made with pig heart and blood. A French recipe for cœur de porc à l'orange is made of braised heart with an orange sauce. Snake heart, called tim rắn in Vietnam, is sometimes a delicacy consumed in wine.
== Research == Other therapies are under investigation, including gene therapy. BioMarin is conducting clinical trials to investigate PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase or 'PAL'), which is an enzyme substitution therapy in which the missing PAH enzyme is replaced with an analogous enzyme that also breaks down Phe (to ammonia and trans-cinnamic acid). PEG-PAL was in Phase 2 clinical development as of 2015, but was put on clinical hold in September 2021. In February 2022, the FDA issued a statement requiring further data from non-clinical studies to assess oncogenic risk resulting from PEG-PAL treatments.
== Image and legacy == Noriega's authoritarian rule of Panama has been described as a dictatorship, while Noriega himself has been referred to as a "strongman". A 2017 obituary from the BBC stated that Noriega "was an opportunist who used his close relationship with the United States to boost his own power in Panama and to cover up the illegal activities for which he was eventually convicted". A 2010 article in The Guardian referred to him as the best known dictator of his time, and as "Panama's answer to Libyan leader Colonel Muammar Gaddafi". Dinges writes that though Noriega's regime saw a number of murders and crimes, they were similar in scale to those that occurred at the same time under the authoritarian governments of Guatemala, Chile, Argentina, and El Salvador; these governments never saw the level of condemnation from the U.S. that Noriega's did. Others likened him to former Iraqi president Saddam Hussein. Like Saddam, Noriega enjoyed brief U.S. support until he turned into an enemy. After Noriega's death, an article in The Atlantic compared him to Castro and Augusto Pinochet, stating that while Castro had been the nemesis of the U.S., and Pinochet had been its ally, Noriega had managed to be both. It called Noriega the archetype of U.S. intervention in Latin America: "The lawless, vicious leader whom the U.S. cultivated and propped up despite clear and serious flaws." The author stated that although Panama was a freer democracy after Noriega's removal, it was still plagued by corruption and drug trafficking, while Daniel Ortega, whom the U.S.
== History == This condition was first described in 1954 by Janeway, who reported five cases of the disease in children. In 1957 it was further characterized as "a fatal granulomatosus of childhood". The underlying cellular mechanism that causes chronic granulomatous disease was discovered in 1967, and research since that time has further elucidated the molecular mechanisms underlying the disease. Use of antibiotic prophylaxis, surgical abscess drainage, and vaccination led to the term "fatal" being dropped from the name of the disease as children survived into adulthood.
Sources: en.wikipedia.org
Solid NMN is often stored frozen, desiccated, and protected from light. Aqueous solutions are less stable and generally require colder storage or fresh preparation.
Mass spectrometry and nuclear magnetic resonance spectroscopy are used for structural confirmation. Liquid chromatography with ultraviolet or mass spectrometric detection is common for purity and quantity.
No. Chemical purity indicates the material matches specification; it does not demonstrate absorption, biological activity, or clinical benefit. Those questions require controlled human studies.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.